Video

How Does Launching a Personalized Drug Differ from Other Specialty Drugs?

Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.

Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.

Transcript: Every specialty drug is different, so I think that’s what we’ve learned about specialty is there’s not a lot of cookie cutter. So I think a lot of the issues with launching a personalized drug is kind of the same for specialty.

I think the great part about it, is that we can get patients to a treatment that will work for them sooner. A lot of what we go through is a lot of step therapy, which require a lot of [prior authorizations]. There is the issue that usually those therapies are more expensive, so it’s just making sure the appropriate controls are in place, but I think everyone would say they’d rather a patient start on a therapy that’s going to be effective rather than waste money on a product that’s not going to work for the patient. I think what we have to look at is we need to treat these patients as individuals and not the average patient. It gives us the opportunity to tailor a therapy specifically for that patient. I think it changes how we think about treatment a little bit and pharmacy needs to keep up with that also.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
© 2025 MJH Life Sciences

All rights reserved.